MRNA - Comprehensive Filing Intelligence

FY 2025•10-K•Filed Feb 20, 2026
4.0/10
Filing Health:CAUTION

Notable concerns that warrant closer review

Executive Summary

The company continues to invest heavily in pipeline development and manufacturing expansion, leading to significant cash outflows and a projected continuation of negative operating cash flows.. Moderna is engaged in significant, complex, and global patent litigation with major competitors like Pfizer/BioNTech and Arbutus, involving its core mRNA technology and lipid nanoparticles, posing substantial risk to its intellectual property and revenue streams.. Total revenue decreased by 40% year-over-year.

Top Concerns

  • !Revenue declined significantly in 2025 due to lower COVID vaccine demand and the completion of government contracts, though growth is expected to return in 2026.
  • !Liquidity is currently sufficient for the next 12 months, supported by existing resources and a new credit facility, but the company acknowledges risks and uncertainties that could impact financial resources.
  • !Significant inventory write-downs and unutilized manufacturing capacity costs impacting cost of sales.
  • !High degree of management judgment noted in estimating sales returns due to limited historical data.
  • !Moderna is engaged in significant, complex, and global patent litigation with major competitors like Pfizer/BioNTech and Arbutus, involving its core mRNA technology and lipid nanoparticles, posing substantial risk to its intellectual property and revenue streams.

Top Positives

  • +Operating expenses, particularly R&D and SG&A, were reduced in 2025 through cost discipline and operational streamlining, which improved the operating loss.

Analysis Dimensions

Our 5-pass AI analysis examines this filing across multiple dimensions. Each dimension score is derived from direct analysis of SEC filing text.

Narrative Intelligence

7.0/10

Management tone is balanced.

Full analysis includes: tone changes vs prior quarter, margin driver breakdown, forward guidance analysis, strategic priorities.

Accounting Quality

6.0/10

Earnings quality shows moderate accounting practices.

Full analysis includes: reserve and allowance changes, non-recurring item analysis, stock-based compensation impact, disclosure concerns.

Hidden Liabilities

Off-balance sheet risk is elevated with $2.8 billion in identified exposure.

Full analysis includes: cloud and purchase commitments, VIE/SPE exposure, covenant compliance status, refinancing risk assessment.

Risk Landscape

3.0/10

Overall risk profile shows regulatory and market uncertainty as primary concern.

Full analysis includes: 8 risk categories with severity, new vs escalated risks, management response assessment, risk trend analysis.

Segment Performance

4.0/10

Segment health analysis.

Full analysis includes: segment-by-segment revenue breakdown, geographic concentration risk, customer concentration analysis, segment margin trends.

Related Research

Analysis

MRNA 10-K Analysis: The 78% Margin Platform Hidden Behind -158% Operating Losses